To study whether the addition of lignocaine, a local anesthetic (pain relieving) drug, to steroid which is being given by direct injection into the joint have any benefit in cases of arthritis.
Phase 4
- Conditions
- Health Condition 1: M468- Other specified inflammatory spondylopathiesHealth Condition 2: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2024/01/061287
- Lead Sponsor
- Department of Internal MEdicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Diagnosed as a case of rheumatoid arthritis or spondyloarthritis
2. Having bilateral symmetrical swollen joints - either both shoulders or knees or ankles or elbows planned for joint injections
Exclusion Criteria
1. Patient refusal to participate in study
2. Allergy to Lignocaine or Methyl-Prednisolone acetate
3. Joints are damaged
4. Inability of the patient to be able to understand or give pain scores
5. Non-symmetrical joint involvement (Symmetry as assessed by physician)
6. Standard exclusion for any intra-articular steroids including Septic-arthritis or overlying skin infection,Coagulopathy, Joint Prosthesis, Intra-articular fracture
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in joint-painTimepoint: 1-hour
- Secondary Outcome Measures
Name Time Method Improvement in Joint-pain at 1-day between the IAC+LA versus IAC aloneTimepoint: 1 day;Improvement in Joint-pain at 1-week between the IAC+LA versus IAC aloneTimepoint: 1 week;Procedural pain between the IAC+LA versus IAC aloneTimepoint: immediate;Relapse rates at 3 months post intra articular injectionTimepoint: 3 months